fbpx

We are
Cybin

A leading Life Sciences Company
 

Company Highlights

With 1 in 4 people affected by mental or neurological disorders, our aim is to become the first life sciences company to bring a psilocybin drug to market targeting Major Depressive Disorder (MDD). 

Cybin is a leading Life Sciences Company focused on psychedelic drug development, unique delivery mechanisms, improved novel compounds and protocols that target psychiatric and neurological conditions.

IP Strategy

Covering chemically synthesized compounds, delivery mechanisms, screeners & protocols and new drug formulations.

Fully Approved Psilocybin

Cybin aims to become one of the first life sciences companies to launch a fully approved psilocybin product targeting depression.(2)(3)

Funding

Approx $55M successfully raised thus far from Seed, Series-A and Series-B rounds.

Strategic Shareholders

Strategic shareholder base with long term investment thesis including biotech funds and former heads of top fortune 100 CPG companies.

Medical Team

Has run multiple clinical trials and facilitated over C$1B in pharma sales.

M&A Strategy

To attain intellectual property, capabilities and revenue that strategically align with the business(2)

  1. https://www.psychedelicscience.ca/publications
  2. Forward-looking statements are subject to various risks and assumptions. See “Cautionary Statement Regarding Forward-Looking Information” on page 2 of this presentation.
  3. Subject to receipt of all necessary regulatory approvals

Operating Divisions

Wholly-owned subsidiary of Cybin Corp.

Cybin - Oral Film

Serenity Life Sciences Inc.

Big pharma has had a 10+ year stalemate on any new drug innovations surrounding mental illness. We believe the next 10 years of newly discoverable data from psychedelic studies can potentially create an entirely new marketplace of safe and effective drugs derived from psychedelics.

Journey™ Nutraceutical
Mushroom Products.

Journey™ is being positioned for accelerated growth within North America through: (1)

  • A key focus on medicinal mushrooms 
  • Proprietary formulations & clinically backed ingredients
  • Proprietary form factors
Journey-1024x800-1-edited

Pre-Clinical Studies

Clinical Trials

Cybin Clinical Trial to be conducted in Patients with Major Depressive Disorder (MDD).(1)(2) 

Clinical Trial:
Phase 2

A Phase 2, Randomized, Parallel Group, Bioequivalence (BE) Study of Psilocybin 1 mg, 3 mg, 5 mg and 7 mg administered with sublingual film to 25 mg Oral Capsule Followed by Placebo-Controlled Safety and Efficacy Trial with Selected Dose in Patients with Major Depressive Disorder (MDD).

0
Sublingual Film Doses
0
Patients
0
Month Period

Management Team

Management and advisory team has vast experience within the psychedelic, pharmaceutical and nutraceutical sectors.

Doug Drysdale

CHIEF EXECUTIVE OFFICER

  • Seasoned Corporate Director and CEO who has built and turned-around 3 pharmaceutical companies including a NASDAQ-listed company, raising over $4B of public and private capital. 
  • Grew revenues from inception to $450MM US as Founding CEO of Alvogen Group. 
  • Chairman and CEO of Pernix Therapeutics achieving $465M of raised capital and enterprise value growth from $80M to $800M. 
  • Lead 15 corporate acquisitions across 3 continents at Actavis Group, raising $3B of capital leading to successful sale for EUR4.25B to Watson Pharmaceuticals.
  •  30+ years of pharma and healthcare experience, winner of the Entrepreneur of the Year award by Ernst and Young (2012).
  • Bachelor degree in Microbial and Molecular Biology from the University of East Anglia (UK). 

Paul Glavine

Co-founder & CHIEF OPERATING OFFICER

  • Serial entrepreneur and investor with vast experience in the biotech and cannabis sectors.
  • Co-founder of Global Canna Brands which was granted the first ever tier 3 cultivation license in Jamaica.
  • Sold first cannabis start up TruVerra to Supreme Cannabis Company Inc. (TSX:FIRE).
  • Previous background in the technology industry, has advised on M&A and other financings in excess of $50M.

Eric So

Co-founder & President

  • Co-founder and Managing Director of Trinity Venture Partners Inc., a Canadian boutique merchant bank.
  • A trusted advisor, he began his career practicing in the areas of corporate commercial, securities, finance and mergers and acquisitions at a leading international law firm.
  • Successfully raised over $70M for his multiple start-ups.
  • Co-founder of Growpacker Inc.

John Kanakis

Co-founder & SVP Business Development

  • Co-Founder and Managing Director of Trinity Venture Partners Inc, a Canadian boutique merchant bank.
  • Co-Founder of Growpacker Inc., a private and profitable contract manufacture of cannabis infused beverages and edibles that operates in California.
  • 10+ years experience in medical device and CPG manufacturing.
  • Early stage investor and advisor in various companies spanning multiple sectors.

Greg Cavers

CHIEF FINANCIAL OFFICER

  • 15+ years experience creating efficient scalable operations financial reporting, IFRS; regulatory reporting OSFI.
  • Former Ontario Securities Commission contracted Director of Finance.
  • Former Scotiabank senior manager of enterprise functions.
  • Former CFO of Global Maxfin Investments Inc.
  • Former CIBC small business lending controller. Authority over assets of $31B for external reporting on a monthly and quarterly basis.

Jukka Karjalainen
Ph.D., M.D

Chief Medical Officer

  • Former Director of Medical and Regulatory Affairs and Corporate Vice President at Biovail Pharmaceuticals. Former Medical Director at Eli Lilly and Company(Finland) and multiple roles as C-level officer in private biotech companies.
  • 25 years of pharma experience spanning multiple medical specialties, academic, clinical research regulatory affairs, preclinical, regulatory and clinical drug development from Phase I to Phase IV.
  • Designed and managed large number of Phase 1a and b trials, hundreds of Phase 2-3 clinical registration trials, Phase 3b and 4 trials in Europe, Asia, US and Canada.
  • 60 original publications in top-rated international medical journals, author of over 80 CSR’s, 2 health outcome reports and 11 review articles.

Jacqueline Poriadjian

Chief Marketing Officer

  • Entrepreneurial executive with 15+ years of global brand building experience across multiple industries.
  • Extensive management experience, with P&L responsibility for $500 million+ business lines.
  • Former Head of Global Brand Marketing and Managing Director of International Distribution at UFC.
  • Former Chief Marketing Officer at Canada Goose and former Marketing Officer and Chief Revenue Officer at ecobee
  • Serves on the board of The Supreme Cannabis Company Inc. (TSX: FIRE) and various private boards.

Grant Froese

Retail Strategist

  • Former Chief Operating Officer at Loblaws, Canada’s largest food and drug retailer.
  • 38 years experience within the retail industry.
  • Extensive background in merchandising, supply chain management, digital, marketing and innovative strategies.
  • Served on various private and public boards.

Executive Medical & Clinical Advisory Team

Chris Sankey, M.D.

Clinic Advisor 

  • 20 years experience in the field of mental health and addiction and is currently the medical director of First Step Addiction Clinics,  Sunrise Clinics and the staff physician
    at the Satellite Comprehensive Opioid Addiction Treatment Centre in Toronto.

  • Held positions at the University of Toronto and CAMH. For the last decade he has been the Vice Chair of Addiction Medicine for the Ontario Medical Association and
    has worked as supervisor for the College of Physicians and Surgeons of Ontario.

  • Previously appointed to a Minister of Health’s Task Force.

  • Contributed to scientific studies in mental health and was lead author for a recently published paper on patterns of opioid abuse in Ontario.

Doug Sommerville

Chief Pharmaceutical Strategist

  • Former Country Head and Global SVP at Teva Canada, with record revenue exceeding $1.4B – more than 5 billion doses GMP production.

  • 25 years experience in pharma business development, R&D, M&A in domestic and international medical markets.

  • Past Chair of the Canadian Generic Pharmaceutical Association — $6B industry sales.

  • Former Global Vice President at Baxter Healthcare Corporation.

Thomas Anderson

Clinical Research Advisor

  • Research Director and co-founder of the Psychedelic Studies Research Program (PSRP) at the University of Toronto.

  • Co-Founder of the Toronto Centre for Psychedelic Science which has published some of the first academic research on microdosing.

  • PhD candidate and cognitive neuroscientist with the Regulatory and Affective Dynamics (RAD) Lab of Norman Farb, an associate professor of psychology at U of T Mississauga.

  • Thomas’ research is some of the first on psychedelic microdosing.

  • Supported by the Natural Sciences and Engineering Council of Canada (NSERC) and the Stratas Foundation which recently awarded Thomas with an innovation award.

Rotem Petranker

Clinical Research Advisor

  • Associate Director and co-founder of the Psychedelic Studies Research Program (PSRP) at the University of Toronto.

  • Co-Founder of the Toronto Centre for Psychedelic Science which has published some of the first academic research on microdosing.

  • BSc in psychology from the University of Toronto and an MA in social psychology from York University while currently undergoing his PhD candidacy at York University.

  • Main research interests include sustained attention, emotion regulation and creativity which are ostensibly affected by psychedelics.  Clinical interests include disorders amenable to psychedelic psychotherapy, including mood disorders and obsessive compulsive disorder.

Domenico Fuoco, Ph.D.

SVP Scientific Innovation

  • Chemistry background with continued studies that lead to a doctorate in pharmacy at the Universita deali studi di Perugia, Italy, a PhD of pharmacology and toxicology, followed by a post-doctoral fellowship in supportive and palliative care at McGill University.

  • Founder of Smart Medicines GMP Inc. with vast experience in the pharmaceutical and cannabis industries.

  • Successfully invented, patented and sold 4 inventions to major pharmaceutical companies.

  • Winner of the Dr. Henry Shibata Fellowship award (2015) and the International Year of Biodiversity Chemistry Initiative Award (2010) from the Instituto Italo – Latino Americano.

Thomas Anderson

Clinical Research Advisor

  • Research Director and co-founder of the Psychedelic Studies Research Program (PSRP) at the University of Toronto.

  • Co-Founder of the Toronto Centre for Psychedelic Science which has published some of the first academic research on microdosing.

  • PhD candidate and cognitive neuroscientist with the Regulatory and Affective Dynamics (RAD) Lab of Norman Farb, an associate professor of psychology at U of T Mississauga.

  • Thomas’ research is some of the first on psychedelic microdosing.

  • Supported by the Natural Sciences and Engineering Council of Canada (NSERC) and the Stratas Foundation which recently awarded Thomas with an innovation award.

Executive Research, Clinical and Regulatory Team

Lorenzo Gordon, M.D.

Director of Research

  • Current Vice Dean and Medical Director of the Caribbean School of Medical Sciences, Jamaica (CSMSJ) and is a graduate of the University of the West Indies, Mona.

  • Holds a Doctor of Philosophy in Biochemistry as well as a medical degree from the Higher Institute of Medical Sciences of Havana, Cuba.

  • Over 50 peer-reviewed publications.

  • Currently serves as a member of the Medicinal Cannabis Unit (MCU) Advisory Board Committee, Ministry of Health; and as a consultant to the Economic Growth Council on Cannabis-related matters; the Cannabis Licensing Authority (CLA), The Bureau of Standards; for Protocol Development and Research for cannabis.

Alan Ridgeway Ph.D.

Healthcare Research Advisor

  • Worked as a publishing research analyst for more than 10 years, most recently at Sprott Capital Partners.

  • Prior to joining Sprott Capital Partners, he was a top ranked analyst at Scotiabank covering the healthcare sector.

  • Before working in the capital markets, Mr. Ridgeway held a postdoctoral fellowship at Harvard Medical School where he performed cancer research.

  • Mr. Ridgeway holds a Ph.D. in Biochemistry from Western University, an MBA from Queen’s University and is a CFA® Charterholder.

James Andrews

Chief Cultivation & Extraction Officer

  • Vast experience in mushroom cultivation in Europe since 2006 with further knowledge in sclerotia production for the Dutch markets and mycelium sub-strain isolation and cultivation preparation.

  • Experience in product formulation, infusion and delivery mechanisms.

  • Transitioned genetics, cultivation and extraction expertise into the cannabis industry and consulted with multiple companies on output efficiency both in the USA and Canada.

Lori Challenger

Director of Operations & Compliance

  • Former Lead Compliance Program Designer of the non-medical cannabis compliance program at a major Canadian retailer.

  • ISO 19600 Certified Senior Lead Compliance Manager and PROSCI Certified Change Management Practitioner.

  • Vast knowledge in design and operation of “audit ready” compliance programs, regulatory and operations risk identification, mitigation, corrective action and management.

Natwaine Gardner, M.D.

Director of Product Development

  • Biochemist by profession, Dr. Gardner holds a wealth of knowledge in applied organic chemistry and in research and product development. Dr. Gardner has obtained a BSc Biotechnology (hons) and PhD Biotechnology (high 7 commendation) from the University of the West Indies, Mona in the areas of substance abuse and addiction treatment.

  • Numerous peer reviewed articles in the field of treating substance use disorders and has most recently served as a consultant to implementing the Medicinal Cannabis Unit, Ministry of Health; as well as in research and product development focusing on cannabis-related products.

  • Over 50 peer-reviewed publications.

Sherri M. Altshuler

Regulatory Advisor

  • Partner and Co-Chair of Capital Markets Group at Aird & Berlis LLP.

  • Recognized in 2017 as one of Lexpert magazine’s Rising Stars: Canada’s Leading Lawyers Under 40 and, in 2018, as a leading lawyer to watch in the area of Corporate Finance & Securities.  Also recognized as a leading lawyer in Cannabis Law by Chambers Canada and The Best Lawyers in Canada.

  • Member of the TSX Venture Exchange Ontario Advisory Committee and a former member of the Ontario Securities Commission Small and Medium Enterprises Committee.

  • Instructor of Corporate Finance course at Windsor Law School.

Government Relations, and Communications

Eric Hoskins, M.D., Ph.D., FRCPC, OC, M.SC.

Government Relations Advisor

  • Former Ontario health minister responsible for one of the largest health care systems in North America (2014 – 2018).

  • Former elected Member of Ontario Provincial Parliament with Cabinet positions in Health, Economic Development and Trade, Children and Youth Services, and Immigration.

  • Government of Canada Chair, Advisory Council on the Implementation of National Pharmacare.

  • Physician and public health specialist with more than thirty years’ experience in public policy, complex diplomacy, international affairs, health care, media and economic development at the intersection of business, politics and complex social and political circumstances.

  • Proven negotiator and navigator at the highest levels of government and bureaucracy.

Aleksandar Stosic

Government Relations Advisor

  • Founding Partner and CEO at Stosic & Associates, a Canadian boutique government relations firm.

  • Executive Director to two senior Ontario Cabinet Ministers, including the Minister of Economic Development, Infrastructure, and Trade.

  • Has held senior roles at the Privy Council Office in Ottawa, the Toronto Region Board of Trade, and internationally in the natural resources sector.

  • Currently completing his PhD in Political Science.

Derrick Araneda

Government Relations Advisor

  • Partner at Stosic & Associates, a Canadian boutique government relations firm.

  • Chief of Staff to Ontario Minister of Health & Long-Term Care from 2016 – 2018.

  • Director roles from 2014-2016 with Ontario Government.

  • MBA, IE Business School, Madrid, Spain.

  • Previous work experience in Japan & Spain with high-growth education & technology start-ups.

Sara Brittany Somerset

Chief Communications Officer

  • Award-winning journalist and current contributor to Forbes, Leafly and a plethora of additional media outlets with 2 decades of PR experience.

  • United Nations-based reporter and photographer.

  • First and only full time cannabis correspondent™ in the United Nations press corps, initially covering the U.N. Office on Drugs and Crime.

  • Former U.N. Bureau Chief of High Times.

  • 2018 Star Media award for best cannabis freelance writer.

Jacqueline Poriadjian

Chief Marketing Officer

  • Entrepreneurial executive with 15+ years of global brand building experience across multiple industries.
  • Extensive management experience, with P&L responsibility for $500 million+ business lines.
  • Former Head of Global Brand Marketing and Managing Director of International Distribution at UFC.
  • Former Chief Marketing Officer at Canada Goose and former Marketing Officer and Chief Revenue Officer at ecobee
  • Serves on the board of The Supreme Cannabis Company Inc. (TSX: FIRE) and various private boards.

Sherri M. Altshuler

Regulatory Advisor

  • Partner and Co-Chair of Capital Markets Group at Aird & Berlis LLP.

  • Recognized in 2017 as one of Lexpert magazine’s Rising Stars: Canada’s Leading Lawyers Under 40 and, in 2018, as a leading lawyer to watch in the area of Corporate Finance & Securities.  Also recognized as a leading lawyer in Cannabis Law by Chambers Canada and The Best Lawyers in Canada.

  • Member of the TSX Venture Exchange Ontario Advisory Committee and a former member of the Ontario Securities Commission Small and Medium Enterprises Committee.

  • Instructor of Corporate Finance course at Windsor Law School.

Advisory Team

Dennis McKenna

Advisor

  • Professional and personal interests are focused on the interdisciplinary study of ethnopharmacology and natural psychedelics.

  • 1979- 84 – Ph.D., Botanical Sciences, University of British Columbia.

  • 1990-93– Director of Ethnopharmacology, Shaman Pharmaceuticals, San Carlos California.

  • 2001-2017 – Adjunct Assistant Professor, Center for Spirituality and Healing, Academic Health Center, University of Minnesota.

  • 1993 – Present — Founding Board member, Heffter Research Institute.

  • 1993 – Organizer and key investigator, Hoasca Project, an international biomedical study of ayahuasca use by the UDV, a Brazilian religion.

  • 2017 – Organized 50th Anniversary Symposium, Ethnopharmacologic Search for Psychoactive Drugs (ESPD50), Buckinghamshire, UK.

  • Spring 2019 – Founded the McKenna Academy of Natural Philosophy as a provincial non-profit in British Columbia.

Michael Auerbach

Advisor

  • Entrepreneur, investor, business consultant, media producer, and private diplomat. 

  • Founder of Subversive Capital, which is dedicated to investing in radical companies whose core missions subvert the status quo and require sophisticated government and regulatory strategies for success.

  • General Partner of Subversive’s venture platform and Opportunity Fund, and Chairman of Subversive REIT LP and Subversive Capital Acquisition Corp.

  • Board member of Tilray, Inc. – the first Nasdaq-listed global cannabis company.

  • In his capacity as a private diplomat, Mr. Auerbach serves as a Senior Vice President at Albright Stonebridge Group, the global consulting firm chaired by former Secretary of State Madeleine Albright.

  • Prior to joining ASG, Michael founded and then sold a risk consulting firm to Control Risks – a leading global risk consulting firm. 

  • Michael started his career during the dot-com boom of the late 1990s running Panopticon Inc., a VC incubator concentrating on internet and mobile technology.

  • Held senior positions at the Center for American Progress and The Century Foundation, where he concentrated on issues related to U.S. Foreign Policy, National Security, and Conflict Resolution.

  • Served as a Visiting Professor at the New School for Social Research and also taught at the University of Cape Town and Cyprus College. 

  • Presently sits on the boards of the Theodore C. Sorensen Center for International Peace and Justice, The KiDS Board of NYU’s Hassenfeld Children’s Hospital, Next for Autism, which produces Night of Too Many Stars, and Sophie Gerson Healthy Youth Foundation. 

  • Mr. Auerbach received a M.A. in International Relations from Columbia University and a B.A. in Critical Theory from the New School for Social Research.

Derrick Araneda

Government Relations Advisor

  • Partner at Stosic & Associates, a Canadian boutique government relations firm.

  • Chief of Staff to Ontario Minister of Health & Long-Term Care from 2016 – 2018.

  • Director roles from 2014-2016 with Ontario Government.

  • MBA, IE Business School, Madrid, Spain.

  • Previous work experience in Japan & Spain with high-growth education & technology start-ups.

Press Releases

News

Market Opportunity

US $2.5 Trillion

Global US$800B direct and US$1.7T indirect economic costs from mental disorders(1)

Source: National Centre For Biotechnology Information

US $467 Billion

American direct and indirect economic costs of mental disorders(2)

Source: National Institute of Mental Health

C $51 Billion

Canadian direct and indirect economic costs of mental disorders(3)

Source: Centre for Addiction and Mental Health

Over 700 Million

People are affected globally with some sort of mental illness, addiction or eating disorder(4)

Source: World Health Organization

1 in 4 people

In the world will be affected by mental or Neurological disorders at some point in their lives(5)

Source: World Health Organization

40+ Million

Americans take psychiatric drugs(6)

Source: NBC News

  1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007565/
  2. https://www.nimh.nih.gov/about/directors/thomas-insel/blog/2015/mental-health-awareness-month-by-the-numbers.shtml
  3. https://www.camh.ca/en/driving-change/the-crisis-is-real/mental-health-statistics
  4. (https://www.who.int/whr/2001/media_centre/press_release/en/) & (https://www.mirror-mirror.org/eating-disorders-statistics.htm) & (https://drugfree.org/learn/drug-and-alcohol-news/researchers-release-first-report-worldwide-addiction-statistics/
  5. https://www.who.int/whr/2001/media_centre/press_release/en/
  6. https://www.nbcnews.com/health/health-news/one-6-americans-take-antidepressants-other-psychiatric-drugs-n695141

Market Comparables

Capital Structure

Pro Forma Capitalization of the Business Combination (the “RTO”)

$ 0 K
Founders Round
$ 0 M
Seed Round
$ 0 M
Series A
$ 0 M+
Proposed Offering

Next Round

Treasury offering of a minimum of $14 million and up to $21 million
of subscription receipts (the “Initial Receipts”) of the Company (the “Offering”).

Days
Hours
Minutes
Seconds

Closing Date
August 18, 2020

Contact Us

For more information about Cybin and our products please contact us directly at info@cybin.com.

Contact Us

For more information about Cybin and our products please contact us directly.

Office

5600-100 King Street West Toronto, ON M5X 1C9

Contact Info

Phone: (+876) 423-0521
Email: info@cybin.com